Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: psychopraxis. neuropraxis 6/2017

08.11.2017 | Neurologie

Kognition und MS – ein unterschätztes Problem

verfasst von: Prof. Dr. phil. Dipl.-Psych. Iris-Katharina Penner

Erschienen in: psychopraxis. neuropraxis | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Kognitive Teilleistungsstörungen treten bei Patienten mit Multipler Sklerose häufig auf. Um das kognitive Netzwerk so lange wie möglich zu erhalten, ist eine frühe Immuntherapie wichtig. Der kognitive Status sollte bei jedem neu diagnostizierten Patienten erhoben werden, um einen Verlauf über die Zeit nachvollziehen zu können.
Literatur
1.
Zurück zum Zitat Rao SM et al (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691 CrossRefPubMed Rao SM et al (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691 CrossRefPubMed
2.
Zurück zum Zitat Benedict RH et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12:549–558 CrossRefPubMed Benedict RH et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12:549–558 CrossRefPubMed
3.
Zurück zum Zitat Khalil M et al (2011) Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 17:173–180 CrossRefPubMed Khalil M et al (2011) Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 17:173–180 CrossRefPubMed
4.
Zurück zum Zitat Feuillet L et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 13:124–127 CrossRefPubMed Feuillet L et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 13:124–127 CrossRefPubMed
5.
Zurück zum Zitat Lebrun C et al (2010) Cognitive function in radiologically isolated syndrome. Mult Scle 16:919–925 CrossRef Lebrun C et al (2010) Cognitive function in radiologically isolated syndrome. Mult Scle 16:919–925 CrossRef
6.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444–1452 CrossRefPubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444–1452 CrossRefPubMed
7.
Zurück zum Zitat Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58:1602–1606 CrossRefPubMed Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58:1602–1606 CrossRefPubMed
8.
9.
Zurück zum Zitat Ruet A et al (2013) Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol 260:776–784 CrossRefPubMed Ruet A et al (2013) Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol 260:776–784 CrossRefPubMed
10.
Zurück zum Zitat Benedict RHB et al (2016) Benchmarks of meaningful impairment on the MSFC and BICAMS. Mult Scler 22:1874–1882 CrossRefPubMed Benedict RHB et al (2016) Benchmarks of meaningful impairment on the MSFC and BICAMS. Mult Scler 22:1874–1882 CrossRefPubMed
11.
Zurück zum Zitat Kobelt G et al (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. Epub ahead of print Kobelt G et al (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. Epub ahead of print
12.
Zurück zum Zitat Calabrese M et al (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66:1144–1150 CrossRefPubMed Calabrese M et al (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66:1144–1150 CrossRefPubMed
15.
16.
Zurück zum Zitat Schoonheim MM et al (2015) Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology 84:776–783 CrossRefPubMed Schoonheim MM et al (2015) Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology 84:776–783 CrossRefPubMed
17.
Zurück zum Zitat Langdon DW et al (2012) Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 18:891–898 Langdon DW et al (2012) Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 18:891–898
18.
Zurück zum Zitat Smith A (1973) Symbol Digit Modalities Test Western Psychological Services Smith A (1973) Symbol Digit Modalities Test Western Psychological Services
19.
Zurück zum Zitat Helmstaedter C, Lendt M, Lux S (2001) Beltz Test GmbH, Göttingen Helmstaedter C, Lendt M, Lux S (2001) Beltz Test GmbH, Göttingen
20.
Zurück zum Zitat Benedict RH et al (1997) Psychological Assessment Resources Inc Benedict RH et al (1997) Psychological Assessment Resources Inc
21.
Zurück zum Zitat Fischer JS et al (2000) Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48:885–892 CrossRefPubMed Fischer JS et al (2000) Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48:885–892 CrossRefPubMed
22.
Zurück zum Zitat Penner IK et al (2012) Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 18:1466–1471 CrossRefPubMedPubMedCentral Penner IK et al (2012) Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 18:1466–1471 CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Patti F et al (2010) Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 16:68–77 CrossRefPubMed Patti F et al (2010) Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 16:68–77 CrossRefPubMed
24.
Zurück zum Zitat Patti F et al (2013) Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One 8:e74111 CrossRefPubMedPubMedCentral Patti F et al (2013) Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One 8:e74111 CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Ziemssen T et al (2014) A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol 261:2101–2111 CrossRefPubMedPubMedCentral Ziemssen T et al (2014) A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol 261:2101–2111 CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Wilken J et al (2013) Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study. Int J MS Care 15:120–128 CrossRefPubMedPubMedCentral Wilken J et al (2013) Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study. Int J MS Care 15:120–128 CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Morrow SA et al (2010) Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 16:1385–1392 CrossRefPubMed Morrow SA et al (2010) Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 16:1385–1392 CrossRefPubMed
28.
Zurück zum Zitat Forsberg L et al (2015) A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of dimethyl fumarate. Poster presented at ECTRIMS 2015 Forsberg L et al (2015) A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of dimethyl fumarate. Poster presented at ECTRIMS 2015
29.
Zurück zum Zitat Benedict RHB et al (2017) Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler J. Epub ahead of print Benedict RHB et al (2017) Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler J. Epub ahead of print
30.
Zurück zum Zitat Benedict, RHB et al (2016) Improved cognitive outcomes in relapsing-remitting multiple sclerosis with daclizumab HYP in the phase 3 DECIDE study. Neurology 86(Suppl.):P3.090 Benedict, RHB et al (2016) Improved cognitive outcomes in relapsing-remitting multiple sclerosis with daclizumab HYP in the phase 3 DECIDE study. Neurology 86(Suppl.):P3.090
31.
Zurück zum Zitat Mäurer M et al (2012) Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Mult Scler. Epub ahead of print Mäurer M et al (2012) Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Mult Scler. Epub ahead of print
32.
Zurück zum Zitat Amato MP et al (2013) Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol 260:1452–1468 CrossRefPubMed Amato MP et al (2013) Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol 260:1452–1468 CrossRefPubMed
33.
Zurück zum Zitat Sandroff BM, Hillman CH, Benedict RH, Motl RW (2015) Acute effects of walking, cycling, and yoga exercise on cognition in persons with relapsing-remitting multiple sclerosis without impaired cognitive processing speed. J Clin Exp Neuropsychol 37:209–2019 CrossRefPubMed Sandroff BM, Hillman CH, Benedict RH, Motl RW (2015) Acute effects of walking, cycling, and yoga exercise on cognition in persons with relapsing-remitting multiple sclerosis without impaired cognitive processing speed. J Clin Exp Neuropsychol 37:209–2019 CrossRefPubMed
34.
Zurück zum Zitat Sandroff BM, Hillman CH, Benedict RH, Motl RW (2016) Acute effects of varying intensities of treadmill walking exercise on inhibitory control in persons with multiple sclerosis: A pilot investigation. Physiol Behav 154:20–27 CrossRefPubMed Sandroff BM, Hillman CH, Benedict RH, Motl RW (2016) Acute effects of varying intensities of treadmill walking exercise on inhibitory control in persons with multiple sclerosis: A pilot investigation. Physiol Behav 154:20–27 CrossRefPubMed
35.
Zurück zum Zitat Vogt A et al (2009) Working memory training in patients with multiple sclerosis - comparison of two different training schedules. Restorative Neurology and Neuroscience 27:225–235 PubMed Vogt A et al (2009) Working memory training in patients with multiple sclerosis - comparison of two different training schedules. Restorative Neurology and Neuroscience 27:225–235 PubMed
36.
Zurück zum Zitat Penner IK, Kappos L, Rausch M, Opwis K, Radü EW (2006) Therapy-induced plasticity of cognitive functions in MS patients: Insights from fMRI. Journal of Physiology Paris 99:455–462DOI: CrossRef Penner IK, Kappos L, Rausch M, Opwis K, Radü EW (2006) Therapy-induced plasticity of cognitive functions in MS patients: Insights from fMRI. Journal of Physiology Paris 99:455–462DOI: CrossRef
37.
Zurück zum Zitat Rosti-Otajärvi EM, Hämäläinen P (2014) Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Systematic Reviews 2:CD9131 Rosti-Otajärvi EM, Hämäläinen P (2014) Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Systematic Reviews 2:CD9131
Metadaten
Titel
Kognition und MS – ein unterschätztes Problem
verfasst von
Prof. Dr. phil. Dipl.-Psych. Iris-Katharina Penner
Publikationsdatum
08.11.2017
Verlag
Springer Vienna
Erschienen in
psychopraxis. neuropraxis / Ausgabe 6/2017
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI
https://doi.org/10.1007/s00739-017-0437-z